Latest news with #MarcusCurley
Business Insider
29-05-2025
- Business
- Business Insider
Fisher & Paykel Healthcare Corporation Limited (FSPKF) was downgraded to a Hold Rating at UBS
Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from UBS analyst Marcus Curley today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is ranked #9118 out of 9551 analysts. In addition to UBS, Fisher & Paykel Healthcare Corporation Limited also received a Hold from Morgan Stanley's David Bailey in a report issued on May 27. However, yesterday, Jefferies upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy.
Business Insider
20-05-2025
- Business
- Business Insider
UBS Remains a Buy on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
UBS analyst Marcus Curley maintained a Buy rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is an analyst with an average return of -12.5% and a 44.16% success rate. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fisher & Paykel Healthcare Corporation Limited with a $24.95 average price target. FSPKF market cap is currently $12.8B and has a P/E ratio of 111.53. Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FSPKF in relation to earlier this year.
Business Insider
12-05-2025
- Business
- Business Insider
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from UBS
In a report released today, Marcus Curley from UBS maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per (RMD – Research Report). The company's shares opened today at A$38.26. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Curley is an analyst with an average return of -13.2% and a 42.67% success rate. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per with a A$44.59 average price target. The company has a one-year high of A$40.75 and a one-year low of A$27.13. Currently, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per has an average volume of 1.4M.
Business Insider
07-05-2025
- Business
- Business Insider
UBS Reaffirms Their Hold Rating on SKYCITY Entertainment Group Limited (SKYZF)
In a report released today, Marcus Curley from UBS maintained a Hold rating on SKYCITY Entertainment Group Limited (SKYZF – Research Report). The company's shares closed last Tuesday at $0.76. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Curley is ranked #9046 out of 9472 analysts. The analyst consensus on SKYCITY Entertainment Group Limited is currently a Moderate Buy rating. SKYZF market cap is currently $511.5M and has a P/E ratio of -5.30.
Business Insider
06-05-2025
- Business
- Business Insider
UBS Keeps Their Buy Rating on a2 Milk Company (ACOPF)
In a report released today, Marcus Curley from UBS maintained a Buy rating on a2 Milk Company (ACOPF – Research Report). The company's shares closed yesterday at $5.35. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Curley is an analyst with an average return of -13.2% and a 42.67% success rate. Currently, the analyst consensus on a2 Milk Company is a Moderate Buy with an average price target of $4.75. The company has a one-year high of $5.75 and a one-year low of $2.90. Currently, a2 Milk Company has an average volume of 4,948.
